Oncología Médica Traslacional y Terapia Individualizada del Cáncer

García-Alfonso, P; Alcaide-Garcia, J; Aguilar, EA; Elez, E; Montes, AF; Escobar, IG; Grávalos, C; García, IM; Viladot, CM; Vivas, CS; Sastre, J; Tarazona, N; Jimenez-Fonseca, P.

Definition of lines of treatment in metastatic colorectal cancer: a Delphi consensus

Clinical & Translational Oncology. 2025; : [doi:10.1007/s12094-025-03986-y]

Arranz, JA; Martínez, C; Gallego, L; Heredero, A; Rebollo, P; Fernández, L; Estella, E; Larena, DV; Palomar, V.

Patterns of treatment in first and subsequent lines in RCC in Spain. A real-world descriptive cross-sectional study

Future Oncology. 2025; 21(21): 2767-2774 Nº de citas: 1 [doi:10.1080/14796694.2025.2542030]

Villacampa, G; Pascual, T; Tarantino, P; Cortés, J; Perez-Garcia, J; Llombart-Cussac, A; Conte, P; Mancino, M; Guarneri, V; Dieci, MV; Waks, AG; Schettini, F; Brasó-Maristany, F; Griguolo, G; de Castro, B; Reboredo, C; Antolin, S; Bueno-Muiño, C; Echavarria, I; López-Tarruella, S; Massarrah, T; del Monte-Millán, M; Martin, M; Buckingham, W; Parker, JS; Vivancos, A; Polyak, K; Metzger, O; Cwolff, A; Demichele, A; Tung, NM; Perou, CM; Paré, L; Villagrasa, P; Prat, A; Tolaney, SM.

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis

LANCET ONCOLOGY. 2025; 26(8): Nº de citas: 13 [doi:10.1016/S1470-2045(25)00276-1]

Cherny, NI; Oosting, SF; Dafni, U; Latino, NJ; Galotti, M; Zygoura, P; Dimopoulou, G; Amaral, T; Barriuso, J; Calles, A; Kiesewetter, B; Gomez-Roca, C; Gyawali, B; Piccart, M; Passaro, A; Roitberg, F; Tarazona, N; Trapani, D; Curigliano, G; Wester, R; Zarkavelis, G; Zielinski, C; Vries, EGED.

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)

ANNALS OF ONCOLOGY. 2025; 36(8): 866-908 Nº de citas: 24 [doi:10.1016/j.annonc.2025.04.006]

Graff, JN; Burotto, M; Fong, PC; Pook, DW; Zurawski, B; Kopp, RM; Salinas, J; Bylow, KA; Kramer, G; Ratta, R; Kwiatkowski, M; Retz, M; Kwak, C; Arija, JAA; Gurney, H; Matsubara, N; Villanueva, L; Todenhöfer, T; Liang, LW; Todoric, J; Imai, K; Stenzl, A.

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study

ANNALS OF ONCOLOGY. 2025; 36(8): 976-987 Nº de citas: 15 [doi:10.1016/j.annonc.2025.05.007]

Toledano-Fonseca, M; Cano-Osuna, MT; Elez, E; Soto-Alsar, J; Paáez, D; Fernández-Montes, A; Graña, B; Salud, A; Yubero, A; Macías, I; Quintero, G; López-López, C; Fernández-Rodríguez, T; García-Ortiz, MV; Sastre, J; García-Alfonso, P; Rodríguez-Ariza, A; Aranda, E.

Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2025; : [doi:10.1111/eci.70103]

Ayala-de Miguel, P; Muñoz-Couselo, E; Gutiérrez-Sanz, L; Fernández, LA; Navarro-Pérez, V; Berciano-Guerrero, MA; García-Arroyo, F; de la Rosa, C; Cerezuela-Fuentes, P; Majem, M; Campos-Balea, B; Soria, A; Hernández-Marín, B; García-Castaño, A; Martin-Algarra, S; Marquez-Rodas, I.

Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)

Clinical & Translational Oncology. 2025; : Nº de citas: 1 [doi:10.1007/s12094-025-04005-w]

Stecklein, SR; Martin, M; Villacampa, G; del Monte-Millan, M; Yoder, R; Pathak, H; Cobo, S; Brasó-Maristany, F; Alvarez, EL; Echavarría, I; Bueno-Muiño, C; Jerez, Y; Cebollero, M; Bueno, O; García-Saenz, JA; Moreno, F; Gómez, HL; Massarrah, T; Herrero, B; Paré, L; Marín-Aguilera, M; Buckingham, W; López-Tarruella, S; Villagrasa, P; Godwin, AK; Salgado, R; Prat, A; Sharma, P.

Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer

JNCI-Journal of the National Cancer Institute. 2025; : [doi:10.1093/jnci/djaf162]

Alfano, F; Navas, P; Lamata, P; García, KF; Ortuño, JE; Zamora, OB; Lizarraga, S; Santos, A; Pascau, J; Goicolea, JM; Ledesma-Carbayo, MJ.

Patient-specific visco-hyperelastic mechanical model for breast tumor localization in surgical planning

Bioengineering & Translational Medicine. 2025; 11(1): [doi:10.1002/btm2.70044]

Calles, A; Navarro, A; Uribe, BGDD; Colomé, EA; de Miguel, M; Alvarez, R; Arregui, M; Moreno, V; Rocha, P; Calvo, E; Ramon-Patino, J; de la Fuente, EC; Alcalá-López, D; Boix, O; Fernández-Pinto, M; Rodríguez-Morató, J; Palmero, R; Nadal, E; Jove, M; Felip, E.

Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study

Journal of Thoracic Oncology. 2025; 20(7): 969-982 Nº de citas: 10 [doi:10.1016/j.jtho.2025.02.005]

Adrián SG; Pérez CI; Carmona-Bayonas A; Morán LO; Pérez JR; Del Prado PM; De Castro EM; Neria F; Pérez IF; De Herreros MG; Campos MC; Escobar IG; Balanyà RP; González DM; Fonseca PJ; García MEG; Cánovas MS; Langa JM; Segura PP; Vidal MJM; Martín AJM.

Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding.

HAEMATOLOGICA. 2025; 110(7): 1513-1522 Nº de citas: 3 [doi:10.3324/haematol.2024.286152]

Vedovati, MC; Martín, AJM; Giustozzi, M; Jimenez-Fonseca, P; Becattini, C; del Prado, MPM; Dentali, F; Huisman, M; Cohen, AT; Bauersachs, R; Carmona-Bayonas, A; Agnelli, G.

Derivation and validation of the Caravaggio score for the risk stratification for recurrence in patients with cancer-associated venous thromboembolism

European Journal of Internal Medicine. 2025; 137: 67-72 Nº de citas: 4 [doi:10.1016/j.ejim.2025.04.016]

Agrawal, YN; Fernandez-Martinez, A; Gil-Gil, M; Zielinski, C; Ruiz-Borrego, M; Ciruelos, EM; Munoz, M; Margeli, M; Bermejo, B; Anton, A; Kahan, Z; Csoeszi, T; Alonso-Romero, JL; Garcia-Saenz, JA; Sanchez-Rovira, P; Alvarez, E; Chacon, JI; Gonzalez-Santiago, S; Rodriguez, CA; Servitja, S; Pfefferle, AD; Herranz, J; Liu, Y; Carey, LA; Romero-Camarero, I; Caballero, R; Guerrero-Zotano, A; Perou, CM; Martin, M.

Transcriptomic Predictors of Survival for Palbociclib plus Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial

JCO Precision Oncology. 2025; 9: [doi:10.1200/PO-24-00937]

Loibl, S; Martin, M; Bonnefoi, H; Untch, M; Kim, SB; Bear, HD; García-Sáenz, JA; Olivé, MM; Mc Carthy, N; Gelmon, K; Kelly, CM; Im, SA; Reimer, T; Martinez-Janez, M; Zhang, Z; Toi, M; Provencher, L; Rugo, HS; Gnant, M; Makris, A; Torres, AA; Hirmas, N; Holtschmidt, J; Nekljudova,; Marmé, F.

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HRD/HER2L breast cancer and residual disease after neoadjuvant chemotherapy

ANNALS OF ONCOLOGY. 2025; 36(7): 832-837 Nº de citas: 9 [doi:10.1016/j.annonc.2025.03.010]

Felip, E; Rojas, CI; Schenker, M; Kowalski, DM; Casarini, IA; Csöszi, T; Sendur, MAN; Martins, J; Blanco, AC; Wang, C; Wang, M; Fallas, RALR; Yoshioka, H; Nair, S; Song, X; Deng, X; Lala, M; Eiras, R; Takahashi, T.

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial

ANNALS OF ONCOLOGY. 2025; 36(7): 775-785 Nº de citas: 19 [doi:10.1016/j.annonc.2025.03.012]

Chi, KN; Mckay, RR; Sandhu, S; Arranz, JA; Barthelemy, P; Hadaschik, B; Matsubara, N; Shore, ND; Ye, DW; Cascella, T; Irincheeva, I; Kreiser, S; Thiery-Vuillemin, A; Rathkopf, DE.

rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC

Future Oncology. 2025; 21(14): 1771-1777 Nº de citas: 5 [doi:10.1080/14796694.2025.2502318]

Calles A; Calvo E; Santamaría Nuñez G; Costanzo F; Guillén MJ; Martinez Diez M; Gupta A; Cuevas C; Egly JM; Aviles P.

Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in Combination Therapies in Small Cell Lung Cancer.

MOLECULAR CANCER THERAPEUTICS. 2025; 24(6): 828-839 Nº de citas: 5 [doi:10.1158/1535-7163.MCT-24-0050]

Martín, AJM; Castet, F; Alsar, JS; Adeva, J; Peinado, P; Graña, B; Díaz, IA; Rodríguez-Alonso, RM; de Mena, ML; Vera, R; de Mena, IR; Aguilar, S; Vega, S; Morán, LO; Macarulla, T.

MDM2 amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry

ESMO Gastrointestinal Oncology. 2025; 8: 100187-100187 Nº de citas: 1 [doi:10.1016/j.esmogo.2025.100187]